Approved indications (U.S.)

- Adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more disease‑modifying antirheumatic drugs (DMARDs).
- Neonatal‑onset multisystem inflammatory disease (NOMID), a severe form of cryopyrin‑associated periodic syndromes (CAPS); use is typically weight‑based and guided by specialists.
- It is also used for deficiency of the interleukin‑1 receptor antagonist (DIRA) and other rare IL‑1–mediated autoinflammatory diseases under specialist care, though regulatory status can vary.

Off‑label uses and evidence

- Often used off label for other IL‑1–driven conditions such as adult‑onset Still’s disease, systemic juvenile idiopathic arthritis flares, recurrent pericarditis, and some cytokine‑storm syndromes, supported mainly by small clinical trials, observational studies, and expert consensus.
- Has been used off label in certain severe COVID‑19–related hyperinflammatory states when other options are limited, based on emerging but still evolving evidence.

Efficacy expectations

- In rheumatoid arthritis, some patients notice symptom improvement within 1–4 weeks, with maximal benefit often by about 3 months of continuous therapy.
- In NOMID and similar autoinflammatory syndromes, fever and rash may improve within days to weeks, with longer‑term treatment needed to control organ inflammation and prevent damage.
- Compared with other biologic DMARDs (such as TNF inhibitors), Kineret can be somewhat less potent for typical rheumatoid arthritis but may be particularly effective when IL‑1 is a key driver of disease.
- Response varies: some patients achieve substantial symptom relief and better function, while others have only partial improvement and may need alternative or additional therapies.

Typical dosing and how to use

- Rheumatoid arthritis (adults): usual dose is 100 mg injected subcutaneously once daily, at approximately the same time each day.
- NOMID and other IL‑1–mediated autoinflammatory conditions: dosing is based on body weight (mg/kg) and disease severity; injections are given subcutaneously once daily or sometimes divided, under specialist guidance.
- In severe renal impairment, the dose is often reduced to 100 mg every other day for adults, with pediatric adjustments individualized.
- Injections are usually given into the thigh, abdomen, upper arm, or buttock, rotating sites to reduce local irritation; it can be taken with or without food because it is not swallowed.

Special instructions

- Allow the refrigerated syringe to reach room temperature for about 30 minutes before injection; do not warm with hot water or a microwave.
- Do not use the syringe if it has been frozen, dropped and damaged, or if the solution looks cloudy, discolored, or contains particles.
- Follow the injection training provided by your healthcare team and review written or video instructions as needed.

Missed dose guidance

- If a dose is missed, take it as soon as remembered on the same day, then resume the regular schedule the following day.
- If it is almost time for the next dose, skip the missed one and take only the next scheduled dose; do not inject two doses at once to make up for a missed dose.

Overdose

- Taking more than the prescribed amount may increase the risk of infections, low white blood cell counts, or other side effects.
- In case of suspected overdose or repeated extra doses, contact a healthcare provider, local poison control center, or emergency services promptly and bring the medication packaging with you.

Common side effects

- Very common: redness, bruising, itching, or pain at the injection site, especially in the first month; these are usually mild to moderate and tend to lessen over time.
- Other frequent effects: headache, nausea, diarrhea, runny nose, or mild infections such as upper respiratory infections.
- Kineret can lower white blood cell counts (neutropenia), so blood tests are often done, especially early in treatment.

Serious or rare adverse effects

- Serious infections (bacterial, fungal, or opportunistic) can occur and may require hospitalization; treatment may need to be stopped if a serious infection develops.
- Rare cases of severe neutropenia or thrombocytopenia, severe allergic or anaphylactic reactions, and very rarely serious skin reactions have been reported.
- Worsening of pre‑existing kidney problems is possible in very ill patients; dose adjustments may be needed in severe renal impairment.

Warnings and precautions

- Not recommended to combine with TNF inhibitors due to increased risk of serious infections.
- Use with caution in people with chronic or recurrent infections, a history of tuberculosis, or those on other strong immunosuppressants; screening and monitoring are important.
- In pregnancy, Kineret is generally used only if the potential benefit justifies potential risks; limited human data suggest no major safety signal but are not definitive.
- In breastfeeding, small amounts may pass into breast milk; decisions about use should be individualized with the treating clinician.
- Dose adjustment is recommended in severe kidney impairment (creatinine clearance <30 mL/min) because the drug is cleared mainly by the kidneys.
- Safety and dosing in children are condition‑specific and should be overseen by a pediatric specialist experienced with biologics.

Safety compared with similar drugs

- Infection risk is present, as with all biologic immunomodulators, but in many studies Kineret has shown a somewhat lower rate of serious infections than some other biologics when used alone.
- It does not typically carry risks such as demyelinating disease or significant liver toxicity seen with some other agents, but careful monitoring is still required.

Reporting side effects and staying updated

- Patients and caregivers can report suspected side effects to the FDA MedWatch program through their website or by phone, or via their healthcare professional or pharmacist.
- The most current safety communications, including new warnings or recalls, are posted on the FDA and manufacturer websites and may be shared by healthcare providers and pharmacies.

Drug and product interactions

- Combining Kineret with TNF inhibitors (such as etanercept, infliximab, or adalimumab) is not recommended because it increases the risk of serious infections without clear added benefit.
- Use with other biologic immunosuppressants or potent immunomodulators (for example, certain JAK inhibitors) may further raise infection risk and should be carefully evaluated.
- No strong interactions with most common oral medicines, vitamins, or foods are known, but overall immune suppression can increase infection risk when used with corticosteroids or other DMARDs.
- Alcohol does not appear to interact directly with Kineret, but heavy alcohol use may worsen liver or immune function and should be discussed with a clinician.

Precautions and conditions needing caution

- People with active or chronic infections, a history of recurrent serious infections, or untreated latent tuberculosis require careful assessment before starting therapy.
- Caution is advised in patients with severe kidney disease; dose adjustments and closer monitoring are often needed.
- Patients with a history of allergic reactions to anakinra, E. coli–derived proteins, or any component of the formulation should not receive Kineret.
- Vaccinations: live vaccines are generally avoided during treatment; inactivated vaccines are usually acceptable but may be less effective; timing should be planned with the healthcare team.

Monitoring needs

- Regular blood tests, especially complete blood counts, are often done to monitor for low white blood cell counts or other abnormalities.
- Kidney function tests may be checked periodically, particularly in patients with pre‑existing renal impairment or those receiving high or prolonged dosing.
- Disease activity, infection signs (fever, chills, new cough, painful urination), and injection‑site reactions should be reviewed at follow‑up visits to adjust therapy as needed.

Q: How long does it take for Kineret to start working?
A: Some people notice improvement in joint pain or inflammation within a few weeks, but it can take up to about 3 months of regular injections to see the full benefit, especially in rheumatoid arthritis.

Q: Can I give myself Kineret injections at home?
A: Yes, many patients or caregivers give the injections at home after proper training from a healthcare professional on how to store, prepare, and inject the medicine safely.

Q: Is Kineret a chemotherapy drug?
A: No, Kineret is not chemotherapy; it is a biologic medicine that blocks the inflammatory protein interleukin‑1 to reduce immune‑mediated inflammation.

Q: Do I need special blood tests while on Kineret?
A: Your doctor will typically order regular blood tests, especially complete blood counts and sometimes kidney function tests, to monitor for low white blood cell counts, infection risk, and overall safety.

Q: Can I get vaccines while taking Kineret?
A: Many inactivated vaccines can still be given, but live vaccines are usually avoided during treatment, so you should always check with your healthcare provider before receiving any vaccine.

Storage

- Store Kineret prefilled syringes in the refrigerator at 36°F to 46°F (2°C to 8°C); do not freeze.
- Keep in the original carton to protect from light and do not shake the syringe.
- If needed, a syringe may usually be kept at room temperature for a limited time as specified in the package insert, after which it must be discarded.

Handling and disposal

- Inspect the solution before use and do not use if it is cloudy, discolored, or contains particles.
- Use each prefilled syringe only once and dispose of used syringes and needles immediately in an FDA‑cleared sharps disposal container; do not throw loose needles or syringes in household trash.
- Follow local or pharmacy guidance for disposal of full or expired syringes and keep all supplies out of reach of children and pets.